
SNSäžã§ã®HPVã¯ã¯ãã³åé¡ãåå€å±åžã®èª¿æ»ã«ç®ãéããŸãããïŒ
HPVã¯ã¯ãã³ã®å±éºæ§ãäŒããå°æ¹è°å¡ã«å¯ŸããŠãSNSäžã§å€ãã®å»åž«ãè°å¡ãæ¹å€ã®ã³ã¡ã³ããæžããŠããŸããå®å šæ§ã®æ ¹æ ãšããŠãåå€å±ã¹ã¿ãã£ããæããã³ã¡ã³ããèŠãããŸããããã®äººãã¡ã¯ãåå€å±ã¹ã¿ãã£ããšåŒã°ããŠãã調æ»ã«ç®ãéããã®ã§ãããããèªç±èšèŒæ¬ãŸã§ç®ãéããããå®å šã ãšæèšã¯ã§ããªããšæããŸãã
ã³ãã¥ããã£ããŒããšã¯ïŒ
XïŒæ§TwitterïŒã«ãã³ãã¥ããã£ããŒããšããæ©èœãããããã§ãã
ã³ãã¥ããã£ããŒãã¯ãTwitterã§ããæ£ç¢ºãªæ å ±ãå ¥æã§ããããã«ããããšãç®çã«äœãããæ©èœã§ãããã®æ©èœã«ããã誀解ãæãå¯èœæ§ããããã€ãŒãã«ãTwitterãŠãŒã¶ãŒãååããŠèæ¯æ å ±ãæäŸããããšãã§ããŸããååè ã¯ãããããã€ãŒãã«ã³ã¡ã³ããæ®ãããšãã§ããååãªæ°ã®ååè ãããŸããŸãªèŠç¹ããã圹ã«ç«ã£ãããšè©äŸ¡ãããšããã®ã³ã¡ã³ãããã€ãŒãã«è¡šç€ºãããŸããååè ã«ãªãããæ¹ã¯ããã¡ããããç³ã蟌ã¿ããã ããŸãã
ãXãã«ãªã£ãŠãããããŸã ãTwitterããããã€ãŒãããšæžããããŸãŸãªã®ã§ããã€ãŒãã®ãŸãŸã§ããã®ã§ãããããããããããŸããã
ãXãã§çäžããŠãããã€ãŒãã«ã¯ãäžèšã®ãããªã³ãã¥ããã£ããŒããã€ããŠããŸãããä»åã®èšäºã§åãäžããã®ã¯ããã®ã³ãã¥ããã£ããŒãã®ã³ã¡ã³ãã«ã€ããŠã§ãããå ã®çºèšã®æ¯éã§ã¯ãããŸããã

ãªã³ã¯ãèŠããšç«åŠèª¿æ»ãšããã®ããåå€å±ã¹ã¿ãã£ããšåŒã°ããŠãããã®ãæããŠããããã§ãããç£ä¿®ããéŽæšæ°ã¯ãã¯ã¯ãã³ãæ¥çš®ããäººãšæ¥çš®ããŠããªã人ã§å·®ã¯ã¿ãããªãã£ãããšã¯èšã£ãŠããŸãããå ã®è«æã§ããã¯ã¯ãã³ã«ããåŒãèµ·ãããããã®ã§ã¯ãªãã£ãããšæèšã¯ããŠããŸããã
ãããæžããååè
ãšã¯ãã©ã®ãããªç«å Žã®äººãªã®ã§ããããããã¯ã¯ãã³ãæ¥çš®ããäººãšæ¥çš®ããŠããªã人ã§å·®ã¯ã¿ãããªãã£ãããšããèšäºã®èšèã ãã§ã倿ããŠããããã«æããŸãããããæžãã人ããããä¿¡ãã人ã¯ãèšäºã ãã§ã¯ãªããåå€å±åžã®èª¿æ»ã«ãç®ãéããã®ã§ããããã
調æ»çµæã¯ä»ããåå€å±åžã®ãµã€ãã§å
¬éãããŠããŸãã
éµéã§ã®èª¿æ»ã®éç
ãåå€å±ã¹ã¿ãã£ããšåŒã°ããŠããåå€å±åžãè¡ã£ã調æ»ïŒ2015幎ïŒã¯ãåå€å±åžã«äœæ°ç¥šã®ããå°åŠæ ¡ïŒå¹Žçãã髿 ¡ïŒå¹ŽçãŸã§ã®å¥³åçŽïŒäžäººïŒã¯ã¯ãã³æ¥çš®ãæªæ¥çš®åããïŒã«å¯ŸããŠã¢ã³ã±ãŒãïŒèª¿æ»ç¥šïŒãéµéããçŽ3äžäººãè¿éããŸããã調æ»ç¥šã§ã¯ã24é ç®ã«ã€ããŠè³ªåããŠããŸãã
1.æçµäžé ã2.ç°åžžãªéã®æçµæåºè¡ã3.é¢ç¯ãªã©ã®çã¿
4.é床ã®é çã5.ç²åŽæã6.æä¹ åã®äœäž
7.éäžåã®äœäžã8.èŠéã®ç°åžžã9.å ã«å¯Ÿããéææ§
10.çªç¶ã®èŠåäœäžã11.ããŸãã12.è¶³ã®å·æ
13.ç ãã«ã€ãã«ããã14.ç¡ç æéã®ç°åžžãªé·ã
15.èèãã16.éåŒåžã17.èšæ¶åã®äœäžã18.ç°¡åãªèšç®ãã§ããªããªã
19.åºæ¬çãªæŒ¢åãèŠããããªãã20.å¶åŸ¡äžèœãªäžéæéå
21.æ®éã«æ©ãããšãã§ããªãã22.æãè»ãããå¿ èŠã«ãªã
23.çªç¶ã®çåã®äœäžã24.æè¶³ã®è±åæã
ãã®èª¿æ»ãç£ä¿®ããéŽæšè²å€«ææïŒåå€å±åžç«å€§åŠå»åŠéšå ¬è¡è¡çåŠåéïŒã¯ãäžèšã®è«æããŸãšããŸããã
5. Conclusion
In this large-scale survey in Nagoya, Japan, we found that the HPV
vaccines were not significantly associated with the occurrence of 24
reported symptoms, thus suggesting no causal association between the
vaccines and reported symptoms or adverse events.
åå€å±ã§ã®å€§èŠæš¡èª¿æ»ããã¯ãå ±åããã24ã®çç¶ã®çºçãšHPVã¯ã¯ãã³ã¯ææãªé¢é£æ§ã瀺ããªãã£ãããšãããã¯ã¯ãã³ãšå ±åãããçç¶ãŸãã¯æå®³äºè±¡ãšã®éã«å æé¢ä¿ããªãããšã瀺åããŠãããšæžãããŠããŸãã
ã¿ã€ãã«ã¯ãNo associationãïŒé¢é£ããªãïŒãšãªã£ãŠããŸãããçµè«éšåã«ã¯ãã瀺åããŠããããšæžããŠããã ãã§æå®ããŠããŸããã
瀺åããŠãããªãããããå ã«ãããªã調æ»ãè¡ãã¹ãã ã£ãã®ã§ã¯ãªãã§ããããã
æ¥æ¬èªã®è«æãèŠåœãããªãã®ã§ãã³ãã¥ããã£ããŒãã¯äžèšããªã³ã¯ããŠããã®ã ãšæããŸãã
ãããŠããã¯ã¯ãã³ãæ¥çš®ããäººãšæ¥çš®ããŠããªã人ã§å·®ã¯ã¿ãããªãã£ããšããçµè«ãåŸãããŸããããšããéšåãåŒçšããã®ã§ãããã
ããã©ãå
¬éãããŠãã調æ»çµæãèŠãéãããã®èª¿æ»ã¯å®æ
ãç¥ãããã«ã¯éåžžã«éèŠãªæå³ããã£ããšæããŸãããå æé¢ä¿ãããã倿ã§ããã»ã©å³å¯ã«è¡ããããšã¯ãããªããšæããŸããã
åå€å±åžã®ãµã€ãã§ã¯ã調æ»çšçŽãå ¬éãããŠããŸãã
ã å°åŠæ ¡ïŒå¹ŽçããçŸåšãŸã§ã®éã«ã以äžã®ãããªçç¶ãçµéšããããšããããŸããããšãã圢ã§è³ªåããåå ãã¯ã£ããããŠããäžæçãªçç¶ã¯ããããã«å«ããªãã§ãã ããããšæžãããŠããŸãã
å»åž«ããã¢ãªã³ã°ããããã§ã¯ãªãã®ã§ãä¿è·è ã§ãæ¬äººã§ããå³å¯ãªå€æãã§ãããšã¯éããªããšæããŸãã

éµéã§éãããŠããŠãããŸããã£ããèªãŸãã«åçããŠããŸãããšãããã§ããããåçã®å€æã«è¿·ã質åããã£ããããããŸããã
äŸãã°ããéäžã§ããªãããšæããç¶æ
ã«ã¯å人差ããããšæããŸãã
ãã²ã©ãé ãçãããšããã®ããå®ã¯ç®ã®äœ¿ããããšãåå ãããããã©ãæ¬äººããããæèããŠããªããã°ãåå ãã¯ã£ããããŠããäžæçãªçç¶ããšã¯æããªããããããŸãããã§ããããåçã®ä¿¡é Œæ§ã«ã¯ãã©ã€ããããããã«æããŸãã
å®éã«èªç±èšèŒæ¬ãèŠããšãäžèšã®ãããªåçããããŸãã
èªç±èšèŒã質å3

èªåã«åœãŠã¯ãŸããéžæè¢ããªãã£ãããšæžããŠããŸãã仿¹ãªãã©ãããéžã¶å Žåã人ã«ãã£ãŠåçãå€ãã£ãŠããŠããŸãããšãããã§ãããã

ã圱é¿ããªãã£ãããšèšå ¥ãããã圱é¿ããªããšã¯èšããªãç¶æ³ã ã£ãããšã远èšãããŠããŸãã
ããŒã¿ãåæããéã«ã¯ããããã®ã³ã¡ã³ãã¯åæ ãããŠããªãã§ãããããã®ãããªåçã倿°ãããšãããããããããã®ãŸãŸããŒã¿ãšããŠæ±ã£ãŠããé¢ä¿ãªãããšèšã£ãŠãããã®ã§ããããã
ãã®ã»ããã¯ã¯ãã³ãæ¥çš®ããæ¹ã®ã³ã¡ã³ããããã€ã玹ä»ããŸãã


ãã¯ã¯ãã³ãšé¢ä¿ãããã®ã調ã¹ãŠã»ããããšæžããŠããŸãããã®å£°ã¯ãåžãåœã«å±ããã®ã§ããããã


ãã®æ¹ã¯ãæ¥çš®åŸããã«äœãç°åžžããã£ãããã§ã¯ãªãããåŸã ã«äœèª¿ãæªããªã£ããšã®ããšããã®ãããªã±ãŒã¹ãã©ãæ±ãããé£ããã§ãããã


ä»ãç¶ãçµè«ã«å¯Ÿããåè«
ãããŠã24ã®çç¶ã«ã€ããŠãæ¥çš®ãªããæ¥çš®ããã®åçæ°ããŸãšããããŸããã


ããã«ã€ããŠãç£ä¿®ããéŽæšè²å€«ææã¯ããå æé¢ä¿ã瀺ããªããºæ¯ïŒçžå¯Ÿå±éºåºŠïŒã瀺ãã®ãç ç©¶ã®ç®çã§ããããçµæã®ãªããºæ¯ã¯äœãã£ããäžè¬çã«ãªããºæ¯ã2ãäžåããããªæ°åã§è¬å®³ãšå€æããã®ã¯ç¡çããããŸãããšäžèšã®èšäºã§èªã£ãŠããŸãã
éŽæšæ°ã®è«æã«ã€ããŠãè¬å®³ãªã³ããºããŒã¹ã³äŒè°ã¯äžèšã®èŠè§£ã瀺ããŠããŸãã
éå ±ã®è§£æãæ åœããéŽæšææãããããããŠåŠè¡èªã«æçš¿ããè«æ
ã§ãããçµè«ã«ãããŠããã¯ã¯ãã³ãšå ±åãããŠããçç¶ãããã¯å¯åå¿ãšã®éã«å æé¢ä¿ã¯ãªãããšã瀺åãããããšããŠãããããããéŽæšè«æã¯ïœ€äŸç¶ãšããŠé倧ãªåé¡ãæããŠãããäžèšã®çµè«ã¯èª€ãã§ãããšèããã
ãåå€å±åžåå®®é žããäºé²æ¥çš®èª¿æ»ãã«é¢ããéŽæšè²å€«è«æã«ã€ããŠã®èŠè§£ãè¬å®³ãªã³ããºããŒã¹ã³äŒè°ãïŒ2018幎幎6æ11æ¥ïŒ
ãã®åè«ã«å¯Ÿããåçã«ãéŽæšæ°ã¯äžèšã®ããã«æžããŠããŸãã
2018 幎 8 æ 8 æ¥
ããåå€å±åžåå®®é žããäºé²æ¥çš®èª¿æ»ãã«é¢ããéŽæšè²å€«è«æã«ã€ããŠã®èŠè§£ãã«å¯Ÿããåç
åå€å±åžç«å€§åŠå€§åŠé¢å»åŠç ç©¶ç§ å
¬è¡è¡çåŠåé ææãéŽæšè²å€«
ãªããºæ¯ãããã€ã«ãªãããšïŒãã®çµæã«åŸã£ãŠæ¬¡ã®è¡åãæ±ºããã®ã
ç«åŠè ã§ããïŒããŒã¿ãæ éã«éãïŒæ¯èŒå¯èœãªåœ¢ã§ãŸãšãïŒåŠ¥åœæ§ã®é«ãè§£æãããŠïŒçè©°ããšèç¶æ§ã®é«ãæšè«ã§çµè«ããã®ãç«åŠçãªæ¹æ³ã§ããïŒããããã®ä»äºã§ãããšèããŠããïŒ
äžæ¹ãæ±æžå·å€§åŠã¡ãã£ã¢ã³ãã¥ãã±ãŒã·ã§ã³åŠéšææã»éæ¬éŠåœŠæ°ã¯æ°å以å€ã«æ³šç®ããäžèšã®ãããªèŠè§£ãåºããŠããŸãã
â åå€å±ã¹ã¿ã㣠â ãšããç«åŠç ç©¶ã¯ååšããªã
èªç±èšèŒæ¬ã«ããããçå®ã«ç®ãåããã¹ãã§ããããïŒ2021幎5æïŒ
鿬éŠåœŠãïŒæ±æžå·å€§åŠã¡ãã£ã¢ã³ãã¥ãã±ãŒã·ã§ã³åŠéšææã
åå€å±å€§åŠå®¢å¡ææãå
NHK å ±ééšèšè
ïŒ
åå€å±åžèª¿æ»ã®ã»ããšãã®æå³ã¯ãå®ã¯èªç±èšèŒæ¬ã«ãã£ãã
質åãã24 ã®çç¶ã«ããŸãåœãŠã¯ãŸããªã倿§ãªçç¶ãããå Žåã«ããã®ä»ããšããŠèªç±èšèŒããæ¬ããã£ãã®ã ãããããã¹ãŠãå ¬éãããŠããããããèªãã§ã¿ããšããã®èª¿æ»ã®æ¬æ¥ã®ç®çã§ããã被害ã®å®æ ããæããã«ãªã£ãŠãããïŒäžç¥ïŒ
ã¯ã¯ãã³éæ¥çš®çŸ€ã¯ããšããšæç çãé«ããšãããã€ã¢ã¹ã®ååšãè£ä»ãããã®ãšãªã£ãŠããã
èªç±èšèŒæ¬ããã£ããèªãã§ã¿ããšãéæ¥çš®çŸ€ã®èªç±èšèŒæ¬ã«ã¯äžèšã®ãããªã³ã¡ã³ãããããŸãã
èªç±èšèŒã質å2
ã»å 倩æ§ã®é害ããããŸããïŒäºåèæ€çïŒã
ã»å¹³æ24幎2æã«ãç¹çºæ§èŠç¥çµçããçºç ãæ¯å¹Žæ¥ããå ¥é¢ããŠããŸããçŸåšå·Šç®èŠåã0.01ã§ãããèŠéã®æ¬ ãããããŸããåå ã¯äžæã§ãã
ã»3æïœèªéç蚺æãåããŠãããç¥çé床ããããããæ¥åžžäŒè©±ããªãŠã è¿ããæ¬äººã®ææè¡šç€ºçåãããŸããã®ã§ãæ¯ã®èŠãŠåããéšåã®ã¿ãã§ãã¯ãããŠããããŸãããåãããªãæã¯æªèšå ¥ã§ãã
çµ±èšã®åèã«ãªãã®ããªïŒã§ãããšããããè¿ä¿¡ããŸããã
ã»æè·1床ã®Aã®é害ã®ãããæ¬äººã®æããçç¶ã¯ãäžæã
ã»ããããã«ãã§ãã¯ã®ãããã®ã¯ã鿬 乿§è²§è¡ãšã®èšºæãããããããã¡ãã®ã¢ã³ã±ãŒãã«å¯ŸããŠã¯ãããªããã«è©²åœãããããããŸããã
ã»å¹Žæ°ãèšå ¥ããç©ã®äžã«ã¯å°åŠæ ¡6幎çãããåã«çç¶ãåºãç©ãããã®ãŸãŸæžããŠããŸã£ãŠããŸããå¹³æ19幎ãããåã¯ã19幎ããã®ã«ãŠã³ãã§ãé¡ãããŸããç³ããããããŸããã
ãã®ãããªã³ã¡ã³ããç¡èŠããŠåæããæ£ç¢ºãªããŒã¿ãåºããã®ã§ããããããããåã©ãã®é ããæç ããã人ã®åçãå€ãå«ãŸããŠããå Žåãããã®å¹Žä»£ã«ã¯ããããçç¶ã ãããã¯ã¯ãã³æ¥çš®ãšã¯é¢ä¿ãªãããšèšããã®ã§ããããã
ããã«ãåå€å±åžã®èª¿æ»ã§åºãããçµè«ã«ã€ããŠã¯ãè§£æã®ããæ¹ãå€ãããéãçµè«ã«ãªããªã©ãä»ãåè«ãåºãŠããŸãã
ããŒã¿åæãåŠãã§ããåŠçãããŒã¿åæãå°éã«ãããŠããæ¹ã¯ããã²åå€å±åžãå ¬éããŠããããŒã¿ãèŠãŠãèªåãªãã©ãåæãããèããŠã¿ãŠãã ããã
å æ¥æžããäžèšã®èšäºã«ãèšäºå ã§ç޹ä»ãã鿬éŠåœŠæ°ãæ¬äººããã³ã¡ã³ããããã ããåå€å±åžã®èª¿æ»ã«é¢ããè«æãããã€ã玹ä»ããŠããã ããŸããã
ä»ããã¹ãŠã®è«æããã£ãããšèªãäœåããªãã®ã§ã詳ãã玹ä»ããããšãã§ããŸããããããŒã¿åæãåŠãã æ¹ãã¡ã«ãã²ç¥ã£ãŠããã ãããã®ã§æããŠãããŸãã
é æ¬æ°ã幎霢調æŽã®åé¡ç¹ãææããŠããŸãããããã¡ãã§ãåãäžããŠããŸãã
åå€å±åž HPV ã¯ã¯ãã³æ¥çš®åŸèª¿æ»ããŒã¿ãçšãã 2 ã€ã®è§£æè«æã®æ¯èŒãå «éããããèè·¯å åœé倧åŠ
å «éæ°ã¯2019幎ã«ã怿æ°ïŒåŸè¿°ïŒãšåå€å±èª¿æ»ããŒã¿ãç°ãªãè§£æææ³ãçšããŠæ€èšããŠãæ¥æ¬çè·ç§åŠåŠäŒçºè¡ã®è±æèª Japan Journal of Nursing ScienceïŒJJNSïŒã«ãå ±åããŠããŸãã
以äžãåãåå€å±åžèª¿æ»ã®ããŒã¿ãçšããŠéãè§£æãè¡ããçµè«ãç°ãªã£ãŠããè«æã
Safety concerns with human papilloma virus immunization in Japan: Analysis and evaluation of Nagoya City's surveillance data for adverse events
Yukari Yaju, Hiroe Tsubaki
çç¶çºçŸã«äº€äºäœçšãå«ãç«åŠããŒã¿ã®è§£æãâãåå€å±åžåå®®é žããäºé²æ¥çš®èª¿æ»ããã â
èšæ¥œ æ ïŒå
æ ªåŒäŒç€Ÿãã«ã·ã¹ãã 24ïŒ
æ£®å· æåœŠ ïŒå
ä¹
ç米倧åŠãã€ãªçµ±èšã»ã³ã¿ãŒ ææïŒ
äžèšã¯ã2023幎1æã«æçš¿ãããæ°ãããã®ã§ãã
åå€å±åžåå®®é žããäºé²æ¥çš®èª¿æ»ã«é¢ããæ§ã
ãªè°è«ãžã®åçãš2 ã€ã®äº€çµ¡å åã®åæèª¿æŽåæã怿 åºèšãçµ±èšæ°çç ç©¶æ
ã¡ãã£ã¢ã§ã¯åãäžããããŸããããå®å šæ§ã«é¢ããåé¡ã¯æ±ºçããããã§ã¯ãããŸããããµãªããã€ãè¬å®³ã¯ãã¡ã«ããºã ãããããŸã§ã«50幎ããããŸãããä»ã®æ®µéã§ããå®å šãã ãšæèšããããšãªã©ã§ããªãã¯ãã§ãã
HPVã¯ã¯ãã³è¢«å®³è ã®æ¹ãã¡ã«ãã蚎èšãããŸã ç¶ããŠããŸããæ¬¡ã®èšäºã§ãã¢ã¡ãªã«ã§ã®èšŽèšã«ã€ããŠåãäžããäºå®ã§ãã
ã³ãã¥ããã£ããŒãã¯ãã©ã®ãããªç«å Žã®äººãæžããã®ãããããŸããããããéµåã¿ã«ããã«ãããããåŸãè³æã®æ å ±ãªã©ãããèªåã®ç®ã§ç¢ºèªããããšã倧åã ãšæããŸãã